CA
MYGN icon

CSM Advisors’s Myriad Genetics MYGN Stock Holding History

CSM Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,530
Closed -$484K – 144
2021
Q4 		$484K Hold
17,530
– – 0.03% 137
2021
Q3 		$567K Hold
17,530
– – 0.04% 122
2021
Q2 		$536K Sell
17,530
-3,500
-17% -$101K 0.04% 130
2021
Q1 		$640K Buy
+21,030
New +$597K 0.09% 78

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CSM Advisors's MYGN Position: Q1 2022 in Review

CSM Advisors sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 17,530 shares — an estimated $484K sold.

CSM Advisors first reported a position in MYGN in Q1 2021 and held it in 4 quarters. The position peaked at $640K in Q1 2021. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

  • CSM Advisors reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
  • CSM Advisors sold 17,530 Myriad Genetics shares in Q1 2022, an estimated $484K.
  • CSM Advisors first reported a position in Myriad Genetics in Q1 2021 and held it in 4 quarters.
  • CSM Advisors's Myriad Genetics position peaked at $640K in Q1 2021.
  • 205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on CSM Advisors's 13F filing for Q1 2022, filed 16 May 2022.